CB DIAGNOSTICS LUXEMBOURG S.À R.L THE FUNDS (AS DEFINED HEREIN) THERMO FISHER SCIENTIFIC INC. AGREEMENT for the sale and purchase of the entire issued share capital of CB Diagnostics Holding AB 19th May 2011 Freshfields Bruckhaus Deringer LLP 65 Fleet...

the entire issued share capital of CB Diagnostics Holding AB
00 Xxxxx Xxxxxx
Xxxxxx XX0X 0XX
CLAUSE | PAGE | |||
1. SALE AND PURCHASE
|
1 | |||
2. SHARE PRICE
|
1 | |||
3. CONDITIONS TO CLOSING
|
2 | |||
4. PRE-CLOSING SELLER UNDERTAKINGS
|
6 | |||
5. CLOSING
|
6 | |||
6. SELLER WARRANTIES
|
7 | |||
7. PURCHASER WARRANTIES
|
8 | |||
8. RIGHTS OF RESCISSION OR TERMINATION
|
9 | |||
9. POST CLOSING UNDERTAKINGS
|
11 | |||
10. NO LEAKAGE UNDERTAKING
|
12 | |||
11. PAYMENTS
|
12 | |||
12. RESTRICTIVE COVENANTS
|
13 | |||
13. LIABILITY OF THE FUNDS
|
14 | |||
14. ESCROW ACCOUNT
|
14 | |||
15. UPPSALA PROPERTY
|
18 | |||
16. ANNOUNCEMENTS
|
19 | |||
17. CONFIDENTIALITY
|
19 | |||
18. ASSIGNMENT
|
21 | |||
19. FURTHER ASSURANCES
|
21 | |||
20. COSTS
|
22 | |||
21. NOTICES
|
22 | |||
22. CONFLICT WITH OTHER AGREEMENTS
|
23 | |||
23. WHOLE AGREEMENT
|
24 | |||
24. SET-OFF
|
24 | |||
25. WAIVERS, RIGHTS AND REMEDIES
|
25 | |||
26. COUNTERPARTS AND VARIATIONS
|
25 | |||
27. INVALIDITY
|
25 | |||
28. THIRD PARTY ENFORCEMENT RIGHTS
|
25 | |||
29. GOVERNING LAW AND JURISDICTION
|
26 |
CLAUSE | PAGE | |||
SCHEDULE 1 THE FUNDS |
27 | |||
SCHEDULE 2 CONDUCT OF THE TARGET COMPANIES PRE-CLOSING |
28 | |||
SCHEDULE 3 CLOSING ARRANGEMENTS |
33 | |||
A: Seller Obligations |
33 | |||
B : Purchaser Obligations |
33 | |||
C : General |
34 | |||
SCHEDULE 4 PERMITTED LEAKAGE |
35 | |||
SCHEDULE 5 DEFINITIONS AND INTERPRETATION |
36 |
1. | CB DIAGNOSTICS LUXEMBOURG S.À X.X a company incorporated in the Grand Duchy of Luxembourg with registered number B122.409 of 0, xxx Xxxxxx Xxxxxxxxxx, X-0000 Xxxxxxxxxx (the Seller); | |
2. | THE FUNDS, whose respective names and addresses are set out in Schedule 1 (the Funds); and | |
3. | THERMO XXXXXX SCIENTIFIC INC. a corporation incorporated in Delaware, United States of America of 00 Xxxxx Xxxxxx, Xxxxxxx, Xxxxxxxxxxxxx, XXX (the Purchaser), |
Page 1
(a) | (i) expiration or termination of the waiting period applicable to the consummation of the Proposed Transaction under the HSR Act; and (ii) none of the parties hereto being subject to any order or injunction of a court of competent jurisdiction in the United States that prohibits or makes illegal the consummation of the Proposed Transaction contemplated by this Agreement (the US Antitrust Condition); | |
(b) | (i) the European Commission adopting, or having been deemed under Council Regulation (EC) No 139/2004 (the EU Merger Regulation) to have adopted, all decisions and approvals necessary to allow consummation of the Proposed Transaction to occur; and (ii) in the event that all or any part of the Proposed Transaction is referred, or is deemed under the EU Merger Regulation to have been referred, by the European Commission to the competent authorities of one or more EU Member States or EFTA States, all such competent authorities adopting, or having been deemed under relevant laws to have adopted, all decisions and approvals necessary to allow consummation of the Proposed Transaction to occur, or any waiting periods applicable to the Proposed Transaction otherwise having expired or been terminated (the EU Antitrust Condition); | |
(c) | either: |
(i) | the Japan Fair Trade Commission declining jurisdiction over the transaction; or | ||
(ii) | the Japan Fair Trade Commission either granting clearance explicitly or — through the expiration of time periods available for its investigation — being deemed to have granted clearance; or | ||
(iii) | the expiration or termination of any relevant waiting period under applicable Japanese laws (the Japan Antitrust Condition); |
(d) | there shall not have occurred and be continuing any Material Adverse Change; | |
(e) |
(i) | there shall not have occurred and be continuing any material breach by the Seller of its obligations under 4.1 of this Agreement; | ||
(ii) | there shall not have occurred and be continuing any material breach by the Seller of its obligations under clause 10.1 of this Agreement; and | ||
(iii) | the warranties provided by the Seller pursuant to clause 6.1 being true and correct in all material respects at the date of this Agreement and the warranties provided by the Seller pursuant to clause 6.2 being true and correct in all material respects at the Closing Date, |
where the aggregate of: (a) the direct damages (which, for the avoidance of doubt, excludes any Indirect Damages) in respect of clauses 3.1(e)(i) and 3.1(e)(iii), and (b) the Leakage in respect of clauses 3.1(e)(ii) shall exceed €50,000,000; |
Page 2
(f) | the warranties provided by the Purchaser pursuant to clause 7.1 being true and correct in all material respects at the date of this Agreement and the warranties provided by the Purchaser pursuant to clause 7.2 being true and correct in all material respects at the Closing Date it being agreed and understood that, for the purposes of this condition 3.1(f), a warranty shall only be regarded as not being true and correct in all material respects if the direct damages (which, for the avoidance of doubt, excludes any Indirect Damages) that would be suffered or incurred by the Seller as a result of any failure of a warranty to be true and correct in all material respects shall exceed €50,000,000; | |
(g) | the Management Warranties being true and correct in all material respects at the date of this Agreement it being agreed and understood that, for the purposes of this condition 3.1(g), Management Warranties shall only be regarded as not being true and correct in all material respects if the direct damages (which, for the avoidance of doubt, excludes any Indirect Damages) that have been or would be suffered or incurred by the Purchaser and the Target Companies as a result of all such failures of Management Warranties to be true and correct in all material respects at the date of this Agreement shall exceed €250,000,000; | |
(h) | no temporary restraining order, preliminary or permanent injunction or other order preventing, enjoining, restraining or otherwise prohibiting Closing (an Order) has been issued by any court of competent jurisdiction in the United States, Sweden, Japan, France, Germany, Italy, the United Kingdom or Spain (together, the Relevant Countries) and remains in effect, and no law is in force in any of the Relevant Countries that makes Closing illegal; and | |
(i) | there shall not be pending any suit, action or proceeding in which a Governmental Entity of competent jurisdiction in any of the Relevant Countries is seeking: (i) an Order; or (ii) to prohibit the Purchaser’s ownership of the Shares, |
Page 3
(a) | cooperate with each other in connection with any filing or submission with a Governmental Entity under Antitrust Laws and in connection with any investigation or other inquiry by or before a Governmental Entity relating to Antitrust Laws; and | |
(b) | keep the other informed in all material respects and on a reasonably timely basis of any material communication received by such party from, or given by such party to, the Federal Trade Commission, the Antitrust Division of the Department of Justice, or any other Governmental Entity. |
Page 4
(a) | the Seller and the Purchaser shall agree in writing to extend the Longstop Date (such new date being the Extended Longstop Date); or | |
(b) | the Seller or the Purchaser may otherwise elect to terminate this Agreement (other than the Surviving Provisions). |
Page 5
(a) | any inter-company debt (together with any interest thereon, whether accrued, capitalised, paid in kind or otherwise arising) owed by any Target Company to the Seller; and | |
(b) | the PIK Loan Agreement; and | |
(c) | the Facilities by the Borrowers in accordance with the terms of the Facilities Agreement and the release of related Security, and |
Page 6
(a) | the Shares comprise the whole of the allotted and issued share capital of the Company, are fully paid up and the Seller is the sole legal and beneficial owner and is entitled to sell and transfer the full legal and beneficial ownership of the Shares free from Third Party Rights; | |
(b) | this Agreement and each of the documents which are to be entered into by it pursuant to or otherwise in connection with this Agreement will constitute valid and binding obligations of it in accordance with their respective terms; | |
(c) | it is validly incorporated, in existence and duly registered under the laws of its jurisdiction and has full power to conduct its business as conducted at the date of this Agreement; | |
(d) | it has obtained all corporate authorisations and (other than to the extent relevant to the Antitrust Conditions) all other governmental, statutory, regulatory or other consents, licences and authorisations required to empower it to enter into and perform its obligations under this Agreement where failure to obtain them would adversely affect its ability to enter into and perform its obligations under this Agreement; | |
(e) | entry into and performance by it of this Agreement and/or any Transaction Documents to which it is a party will not: |
(i) | breach any provision of its memorandum and articles of association, by-laws or equivalent constitutional documents; | ||
(ii) | (subject, where applicable, to the Antitrust Conditions having been fulfilled) result in a breach of any laws or regulations in its jurisdiction of incorporation or of any order, decree or judgment of any court or any governmental or regulatory authority; or | ||
(iii) | breach any contract, agreement or deed to which it is a party or by which its assets are bound, |
where any such breach would adversely affect its ability to enter into or perform its obligations under this Agreement and/or any Transaction Document to which it is a party; and | ||
(f) | it is not insolvent or bankrupt under the laws of the Duchy of Luxembourg, unable to pay its debts as they fall due or has proposed or is liable to any arrangement (whether by court process or otherwise) under which its creditors (or any group of them) would receive less than the amounts due to them. There are no proceedings in relation to any compromise or arrangement with creditors or any winding up, bankruptcy or insolvency proceedings concerning the Seller and no events have occurred which would justify such proceedings. No steps have been taken to enforce any security |
Page 7
over any assets of the Seller and no event has occurred to give the right to enforce such security. |
(a) | this Agreement and each of the Transaction Documents which are to be entered into by it pursuant to or otherwise in connection with this Agreement will constitute valid and binding obligations of it in accordance with their respective terms; | |
(b) | it is validly incorporated, in existence and duly registered under the laws of its jurisdiction and has full power to conduct its business as conducted at the date of this Agreement; | |
(c) | it has obtained all corporate authorisations and (other than to the extent relevant to the Antitrust Conditions) all other governmental, statutory, regulatory or other consents, licences and authorisations required to empower it to enter into and perform its obligations under this Agreement where failure to obtain them would adversely affect its ability to enter into and perform its obligations under this Agreement; | |
(d) | entry into and performance by the Purchaser and each member of the Purchaser Group of this Agreement and/or any Transaction Documents to which it is a party will not: |
(i) | breach any provision of its memorandum and articles of association, by-laws or equivalent constitutional documents; | ||
(ii) | (subject, where applicable, to fulfilment of the Antitrust Conditions) result in a breach of any laws or regulations in its jurisdiction of incorporation or of |
Page 8
any order, decree or judgment of any court or any governmental or regulatory authority; or |
(iii) | breach any contract, agreement or deed to which it is a party or by which its assets are bound, |
where any such breach would adversely affect to a material extent its ability to enter into or perform its obligations under this Agreement and/or any Transaction Document to which it is a party; | ||
(e) | neither it nor any of its Subsidiaries is insolvent or bankrupt under the laws of its jurisdiction of incorporation, unable to pay its debts as they fall due or has proposed or is liable to any arrangement (whether by court process or otherwise) under which its creditors (or any group of them) would receive less than the amounts due to them. There are no proceedings in relation to any compromise or arrangement with creditors or any winding up, bankruptcy or insolvency proceedings concerning the Purchaser or any of its Subsidiaries and no events have occurred which would justify such proceedings. No steps have been taken to enforce any security over any assets of the Purchaser or any of its Subsidiaries and no event has occurred to give the right to enforce such security; and | |
(f) | the Purchaser has available cash and financing commitment letters, which will at Closing provide in immediately available funds the necessary cash resources to pay the Share Price and meet its other obligations under this Agreement and the Purchaser has made available to the Seller accurate and complete copies of such financing commitments letters which set out all the conditions of drawdown thereunder. |
(a) | by the mutual written consent of the Purchaser and the Seller; | |
(b) | in accordance with clause 3.17; | |
(c) | by the Purchaser if: |
(i) | the Seller commits a breach of any of its obligations under 4.1 of this Agreement; and/or | ||
(ii) | the Seller commits a breach of any of its obligations under 10.1 of this Agreement; and/or | ||
(iii) | the warranties provided by the Seller pursuant to clause 6.1 are not true and correct in all material respects at the date of this Agreement and/or the warranties provided by the Seller pursuant to clause 6.2 are not true and correct in all material respects at the Closing Date, |
Page 9
where the aggregate of: (a) the direct damages (which, for the avoidance of doubt, excludes any Indirect Damages) in respect of clauses 8.1(c)(i) and 8.1(c)(iii), and (b) the Leakage in respect of clauses 8.1(c)(ii) shall exceed €50,000,000; | |||
unless, in each case, the relevant breach or inaccuracy (as applicable) is curable and is cured within 5 Business Days after written notice thereof is given by the Purchaser to the Seller; or |
(d) | by the Seller if the warranties provided by the Purchaser pursuant to clause 7.1 are not true and correct in all material respects at the date of this Agreement and/or the warranties provided by the Purchaser pursuant to clause 7.2 are not true and correct in all material respects at the Closing Date and, for the purposes of this sub-clause, a warranty shall only be regarded as not being true and correct in all material respects if the direct damages (which, for the avoidance of doubt, excludes any Indirect Damages) that would be suffered or incurred by the Seller as a result of any failure of a warranty to be true and correct shall exceed €50,000,000 unless the relevant breach or inaccuracy (as applicable) is curable and is cured within 5 Business Days after written notice thereof is given by the Seller to the Purchaser; | |
(e) | by either the Purchaser or the Seller if: (i) a Governmental Entity in the Relevant Countries shall have issued a final and non-appealable order, decree or ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting Closing; or (ii) there shall be any law, rule or regulation of any of the Relevant Countries promulgated, issued or deemed applicable to the sale and purchase of any of the Shares after the date of this Agreement by any court of competent jurisdiction or other Governmental Entity in the United States or Sweden that would make Closing illegal; or | |
(f) | by the Purchaser if the Management Warranties are not true and correct in all material respects at the date of this Agreement and, for the purposes of this sub-clause, Management Warranties shall only be regarded as not being true and correct in all material respects if the direct damages (which, for the avoidance of doubt, excludes any Indirect Damages) that have been or would be suffered or incurred by the Purchaser and the Target Companies as a result of all such failures of Management Warranties to be true and correct in all material respects at the date of this Agreement shall exceed €250,000,000 unless the relevant breach or inaccuracy (as applicable) is curable and is cured within 5 Business Days after written notice thereof is given by the Purchaser to the Seller. |
Page 10
(a) | properly retain and maintain such records until the earlier of the date that is 7 years after Closing and such time as the Seller agrees that such retention and maintenance is no longer necessary; and | |
(b) | allow the Seller, and its officers, employees, agents, auditors and representatives, to inspect, review and make copies of such records as the Seller may deem necessary or appropriate from time to time, during normal business hours, and with reasonable prior notice, at the expense of the Seller. |
Page 11
(a) | there has not been any Leakage and there will not be any Leakage in the Pre-Closing Period; and | |
(b) | no arrangement or agreement has been made or will be made that will result in any Leakage. |
(a) | the amount of such Leakage; | |
(b) | all reasonable costs incurred by the Purchaser in connection with the collection thereof; and | |
(c) | interest (calculated in accordance with clause 11.4) on such amount from the date of the breach, |
Page 12
(a) | directly or indirectly and whether for its own account or in partnership with another or others or as agent for another or others engage in or be interested in any Competing Business provided the restriction in this sub-clause shall not prevent the Seller or any of the Funds (or any investee entity of any of the Funds) from acquiring or investing in any business which generates less than 30 per cent. of its revenues from Competing Business; | |
(b) | without prejudice to the generality of the provisions contained in clause 12.1(a), directly or indirectly solicit, interfere with or endeavour to entice away from the Purchaser Group any person who is at the date of the Agreement a director or employee of a Target Company whose total annual remuneration is in excess of €125,000 per annum (whether or not such person would commit any breach of his contract of employment or engagement by reason of leaving the service of such company) nor knowingly employ or aid or assist in or procure the employment by any other person, firm or company of any such person, provided that this clause 12.1(b) shall not apply to any such director or employee: |
(i) | responding to a generally advertised position in the course of the usual recruitment processes of the Seller or any investee entity of any of the Funds; or | ||
(ii) | whose employment is terminated other than by reason of voluntary resignation; or |
(c) | without prejudice to the generality of the provisions contained in clause 12.1(a), directly or indirectly solicit or canvas the business of or accept orders from or otherwise deal with any customer or supplier of the Target Companies in relation to in vitro IGE allergy testing products. |
Page 13
(a) | prevent the Seller or any of the Funds (or any investee entity of any of the Funds) from holding, for investment purposes, all and any shares or securities in any body corporate including those dealt in on a recognised investment exchange (as defined by the Financial Services and Markets Xxx 0000 or related legislation) and in each case representing not more than five per cent. of any voting equity in respect of such body corporate; or | |
(b) | apply in the event of a change of control any of the Funds in circumstances where the entity acquiring control carries on (or a member of its group of companies carries on) a business which competes with the Target Companies. |
Page 14
(a) | prior to the First Release Date, the Purchaser shall have notified the Seller in writing of any claim against the Seller pursuant to clause 4.1, 6.1, 6.2 or 10.1 of this Agreement or of any Eligible Management Warranty Claim (a Relevant First Release Claim) stating in reasonably specific detail the nature of the Relevant First Release Claim as then known to the Purchaser (with the Purchaser being required to update the Seller on a reasonably regular basis with any further material details that emerge in due course in respect of such Relevant First Release Claim) and the amount claimed (on a without prejudice basis) in respect of the Relevant First Release Claim (the First Amount Claimed) and provided that the maximum amount the Purchaser shall be entitled to recover in respect of Eligible Management Warranty Claims shall not exceed €25,000,000; and | |
(b) | the Relevant First Release Claim has been Determined (as defined in clause 14.6), |
(a) | on and after the First Release Date but prior to the Second Release Date, the Purchaser shall have notified the Seller in writing of any Eligible Management Warranty Claim (a Relevant Second Release Claim) stating in reasonably specific detail the nature of the Relevant Second Release Claim as then known to the Purchaser (with the Purchaser being required to update the Seller on a reasonably regular basis with any further material details that emerge in due course in respect of such Relevant Second Release Claim) and the amount claimed (on a without prejudice basis) in respect of the Relevant Second Release Claim (the Second Amount Claimed); and | |
(b) | the Relevant Second Release Claim has been Determined, |
(a) | when the First Amount Claimed or Second Amount Claimed (as applicable) is agreed between the Seller and the Purchaser; and |
Page 15
(b) | in the absence of agreement regarding a Relevant First Release Claim or Relevant Second Release Claim (as applicable), on the Business Day following the date when the Relevant First Release Claim or Relevant Second Release Claim (as applicable) has been determined by a Court of competent jurisdiction against which no appeal has been lodged or is capable of being lodged within the statutory time limit. |
(a) | on the First Release Date, an amount equal to the aggregate of €25,000,000 less any amounts paid by the Escrow Agent to the Purchaser in respect of any Relevant First Release Claims (not including any Eligible Management Warranty Claims) in accordance with clause 14.4 shall be paid to the Seller; and | |
(b) | on the Second Release Date, all of the money then standing to the credit of the Escrow Account shall be paid to the Seller. |
(a) | in relation to the First Release Date the aggregate of €25,000,000 less: |
(i) | any amounts paid by the Escrow Agent to the Purchaser in respect of any First Release Claims (not including any Eligible Management Warranty Claims) in accordance with clause 14.10; and | ||
(ii) | all First Amounts Claimed, |
shall be paid on the First Release Date to the Seller; and |
(b) | in relation to the Second Release Date such Second Amount Claimed shall be retained in the Escrow Account and shall not be released to the Seller, other than pursuant to the terms of this clause 14. |
Page 16
(a) | in respect of amounts not released to the Seller on the First Release Date pursuant to clause 14.8, pay such amounts not paid to the Purchaser in settlement of a Relevant First Release Claim to the Seller; and | |
(b) | in respect of the Second Release Date, pay the remaining balance of all monies on the Escrow Account to the Seller. |
(a) | in respect of the portion of the Escrow Amount released on the First Release Date, in accordance with clause 14.7(a), the pro rata proportion of the interest accrued on such portion of the Escrow Amount up to the First Release Date; and | |
(b) | the balance of any interest accrued on the money then standing to the credit of the Escrow Account on the Second Release Date. |
Page 17
(a) | subject only to obtaining confirmation from Lantmäteriet in Uppsala in respect of the necessary cadastral procedure (the Local Authority Consent), the Uppsala Property Disposal is completed as soon as reasonably practicable in accordance with the terms of the Uppsala Property Contract; | |
(b) | it shall use all commercially reasonable endeavours to obtain the Local Authority Consent as soon as reasonably practicable; | |
(c) | it shall keep the Seller reasonably informed as to the progress of the Local Authority Consent and the Uppsala Property Disposal and allow the Seller, and its officers, employees, agents, auditors and representatives, to inspect, review and make copies of such records as the Seller may reasonably deem necessary or appropriate from time to time in connection with the Uppsala Property Disposal, during normal business hours, and with reasonable prior notice, at the expense of the Seller; | |
(d) | not later than the Business Day following the completion of the Uppsala Property Disposal, written notice (the Uppsala Property Disposal Notice) is given to the Seller setting out the Uppsala Property Consideration (and its components), including how it has been calculated and confirming that such calculation has been undertaken in accordance with the terms of this Agreement (and attaching copies of the relevant contracts and documentation); and | |
(e) | within three Business Days of the issuance of the Uppsala Property Disposal Notice, it or any Target Company shall pay by electronic funds transfer for value within five Business Days of completion of the Uppsala Property Disposal to the Seller’s Bank Account the Uppsala Property Consideration. |
Page 18
(a) | a press announcement issued by the Seller and the Purchaser on the date of this Agreement in the Agreed Form; or | |
(b) | the extent that the announcement or circular is required by law, the rules and requirements of the US Securities and Exchange Commission, by any stock exchange or any regulatory or other supervisory body or authority of competent jurisdiction, whether or not the requirement has the force of law. |
(a) | Confidential Information means: |
(i) | (in relation to the obligations of the Purchaser) any information received or held by the Purchaser (or any of its Representatives) relating to the Seller or its parent companies or, prior to Closing, any of the Target Companies; or | ||
(ii) | (in relation to the obligations of the Seller) any information received or held by the Seller (or any of its Representatives) relating to the Purchaser Group or, following Closing, any of the Target Companies; and | ||
(iii) | information relating to the provisions of, and negotiations leading to, this Agreement and the other Transaction Documents, |
and includes written information and information transferred or obtained orally, visually, electronically or by any other means; |
Page 19
(b) | Representatives means, in relation to a party, its respective Subsidiaries and the directors, officers, employees, agents, advisers, accountants and consultants of that party and/or of its respective Subsidiaries. |
(a) | as this clause 17 permits; or | |
(b) | with the prior written approval of (in the case of the Purchaser disclosing) the Seller and (in the case of the Seller disclosing) the Purchaser. |
(a) | disclosure is required by law or the rules and requirements of any listing authority, by any stock exchange or any regulatory, governmental or antitrust body (including any tax authority) having applicable jurisdiction (provided that the disclosing party shall use reasonable efforts to first inform (in the case of the Purchaser disclosing) the Seller and (in the case of the Seller disclosing) the Purchaser of its intention to disclose such information and take into account the reasonable comments of (in the case of the Purchaser disclosing) the Seller and (in the case of the Seller disclosing) the Purchaser); | |
(b) | disclosure is of Confidential Information which was lawfully in the possession of that party or any of its Representatives (in either case as evidenced by written records) without any obligation of secrecy prior to its being received or held; | |
(c) | disclosure is of Confidential Information which has previously become publicly available other than through that party’s fault (or that of its Representatives); | |
(d) | disclosure is required for the purpose of any arbitral or judicial proceedings arising out of this Agreement (or any other Transaction Document); | |
(e) | such disclosure is made on a confidential basis to lending banks or other funding parties or prospective funding (whether debt or equity) parties of the Purchaser; | |
(f) | in the case of the Seller only, such disclosure is made to any of its direct or indirect investors or prospective investors together with their directors, officers, advisors or agents provided that such information is disclosed on a confidential basis; or | |
(g) | in the case of the Purchaser only, the Purchaser may disclose the existence and terms of this Agreement and any other agreements entered into in connection with the Proposed Transaction, and may file a copy of this Agreement and any such other agreements, on a Current Report on Form 8-K and in other filings made by the Purchaser with the U.S. Securities and Exchange Commission after the date of this Agreement, provided that the Purchaser shall not make any such disclosure or filing that contains a reference to Cinven Limited and/or any of the funds managed and advised by Cinven Limited without first using reasonable efforts to consult with Cinven Limited in advance as to the form, content and timing of the disclosure and/or filing as far as is reasonably practicable. |
Page 20
(a) | return to the Seller (or as it may direct) all written documents and other materials relating to the Seller, any Target Company or this Agreement (including any Confidential Information) which the Seller (or its Representatives) has provided to the Purchaser (or its Representatives) without keeping any copies thereof; | |
(b) | destroy all information or other documents derived from such Confidential Information; and | |
(c) | so far as it is practicable to do so, expunge such Confidential Information from any computer, word processor or other device. |
(a) | assign, pledge or otherwise transfer (by way of security or otherwise) its rights and benefits under this Agreement to its lenders in connection with any debt or other financing in respect of the Proposed Transaction; or | |
(b) | assign, pledge or otherwise transfer its rights and benefits under this Agreement to any direct or indirect wholly-owned Subsidiary of the Purchaser provided that, in case of clause 18.2(b), (i) the Purchaser remains liable for such Subsidiary’s due and punctual performance of its obligations hereunder, and (ii) before any such assignee subsequently ceases to be a wholly-owned Subsidiary of the Purchaser, the Purchaser shall ensure that it shall re-assign the benefit to the Purchaser or to another continuing member of the Purchaser Group. |
Page 21
(a) | at the time of delivery, if delivered by hand, registered post or courier; or | |
(b) | at the time of transmission if delivered by fax, |
Page 22
For the attention of:
|
Address: | Fax: | ||
Xxxxxxx Xxxxxx
|
Ballade B2 Building | x000 0000 0000 | ||
0, xxx Xxxxxx Xxxxxxxxxx | ||||
X-0000 Xxxxxxxxxx | ||||
With a copy to:
|
Address: | Fax: | ||
Xxxxx Xxxxxxx
|
Freshfields Bruckhaus | x00 000 000 0000 | ||
Xxxxxxxx LLP | ||||
00 Xxxxx Xxxxxx | ||||
Xxxxxx XX0X 0XX | ||||
The Funds |
||||
For the attention of:
|
Address: | Fax: | ||
Cinven Limited
|
Warwick Court | x00 (0)00 0000 0000 | ||
Xxxxxxxxxxx Xxxxxx | ||||
Xxxxxx XX0X 0XX | ||||
With a copy to:
|
Address: | Fax: | ||
Xxxxx Xxxxxxx
|
Freshfields Bruckhaus | x00 000 000 0000 | ||
Xxxxxxxx LLP | ||||
00 Xxxxx Xxxxxx | ||||
Xxxxxx XX0X 0XX | ||||
Purchaser |
||||
For the attention of:
|
Address: | Fax: | ||
General Counsel
|
00 Xxxxx Xxxxxx, Xxxxxxx, | x00 0 000 000 0000 | ||
Massachusetts, USA | ||||
With copies to: |
||||
Xxx X. Xxxxxxxxx
|
WilmerHale | x0 000 000 0000 | ||
00 Xxxxx Xxxxxx | ||||
Xxxxxx, XX 00000 | ||||
Xxx Xxxxxxxx
|
WilmerHale | x00 (0)00 0000 0000 | ||
Alder Castle | ||||
00 Xxxxx Xxxxxx | ||||
Xxxxxx XX0X 0XX | ||||
Xxxxxx Xxxxxxx |
Page 23
(a) | such other agreement expressly states that it overrides this Agreement in the relevant respect; and | |
(b) | the parties to this Agreement are either also parties to that other agreement or otherwise expressly the parties to this Agreement agree in writing that such other agreement shall override this Agreement in that respect. |
(a) | no party shall have any claim or remedy in respect of any statement, representation, warranty or undertaking made by or on behalf of the other party (or any of its Connected Persons) in relation to the Proposed Transaction which is not expressly set out in this Agreement or any other Transaction Document; | |
(b) | any terms or conditions implied by law in any jurisdiction in relation to the Proposed Transaction are excluded to the fullest extent permitted by law or, if incapable of exclusion, any right, or remedies in relation to them are irrevocably waived; | |
(c) | the only right or remedy of a party in relation to any provision of this Agreement or any other Transaction Document shall be for breach of this Agreement or the relevant Transaction Document; and | |
(d) | except for any liability in respect of a breach of this Agreement or any other Transaction Document, no party (or any of its Connected Persons) shall owe any duty of care or have any liability in tort or otherwise to the other parties (or their respective Connected Persons) in relation to the Proposed Transaction, |
Page 24
Page 25
(a) | the creation, validity, effect, interpretation performance or non-performance of, or the legal relationships established by, this Agreement; and | |
(b) | any non-contractual obligations arising out of or in connection with this Agreement, |
Page 26
(a) | the affairs of each Target Company are conducted only in the ordinary and usual course of business consistent with the manner in which the business of each Target Company was conducted in the twelve month period prior to the date of this Agreement; | |
(b) | it shall co-operate with the Purchaser to allow the Purchaser and its Representatives, upon reasonable advance notice, during normal business hours and without materially interfering with the Target Businesses, reasonable access to the properties, premises, employees, documents, technologies, books, records (including Tax records) and other materials of each Target Company; | |
(c) | no Target Company declares or pays any dividend or other distribution (whether in cash, stock or in kind) other than from one Target Company to another Target Company or reduces its paid-up share capital; | |
(d) | no Target Company: |
(i) | allots or issues or agrees to allot or issue any share or loan capital; or | ||
(ii) | grants any option over or right to subscribe for any share or loan capital, |
(except to another Target Company); |
(e) | no Target Company: |
(i) | employs or agrees to employ any new full or part time persons with a base salary in excess of €125,000 per annum (such person a Senior Employee) or amends the terms of employment of a Senior Employee; | ||
(ii) | makes changes which are outside the ordinary course of business consistent with past practice (other than those required by law) in any terms of employment (including bonus and pension fund commitments) of any employee or independent contractor not being a Senior Employee; | ||
(iii) | dismisses any Senior Employee, except for dismissals for cause or dismissals as required by Plans or agreements in existence as of the date of this Agreement or for any proposed dismissals disclosed in the Data Room; or | ||
(iv) | grants any severance, termination, retention, change-in-control or stay-pay payments (or equivalent payments in any jurisdiction) to any director, officer, employee or individual independent contractor employed or engaged by any Target Company, except as required by the terms of plans or agreements in existence as of the date of this Agreement; |
Page 28
(f) | no Target Company enters into or terminates: |
(i) | any derivative or foreign exchange hedge contract, except for any swap contracts for inter-company cash flows entered into in the ordinary course of business; | ||
(ii) | any contract which has a value or is likely to involve expenditure in excess of €2,000,000 per annum; or | ||
(iii) | any contract which cannot be performed within its terms within three years after the date on which it is entered into; |
(g) | no Target Company institutes any litigation (except in connection with collection in the ordinary course of trading debts) or settles any litigation except for settlements solely in cash involving payments by the Target Companies of no more than €1,000,000 in the aggregate; | |
(h) | no Target Company creates any Third Party Right over the Shares or the shares or assets of any Target Company other than a Permitted Encumbrance, or redeems any existing Third Party Right; | |
(i) | no Target Company makes any acquisition or disposal of any asset other than purchases of raw materials or sales of products in the ordinary course of business consistent with the manner in which the business of each Target Company was conducted in the twelve month period prior to the date of this Agreement, in each case, including consideration, expenditure or liabilities in excess of €500,000 (exclusive of VAT); | |
(j) | no Target Company will make or agree to make, capital expenditures, or incur or agree to incur, a commitment or commitments involving capital expenditures, in each case in excess of €500,000 individually or €2,000,000 in the aggregate and, for the avoidance of doubt, neither the submission by any Target Company of any purchase orders to Aloka under existing terms of business to the extent it is disclosed in the Data Room nor the making of any capital expenditure approved by a Target Company but not made prior to the date of this Agreement to the extent it is disclosed in the Data Room shall require the approval of the Purchaser; | |
(k) | save for the proposed acquisition of an interest in Biomonitor, no Target Company shall acquire an interest in a partnership, limited partnership or a corporate body or merge or consolidate with a corporate body or any other person, enter into any demerger transaction or participate in any other type of corporate reconstruction; | |
(l) | no Target Company shall pass a shareholders’ resolution, except for usual course of business matters consistent with the manner in which the business of each Target Company was conducted in the twelve month period prior to the date of this Agreement or in relation to this Agreement, or if required by law or a Target Company’s organisational documents; | |
(m) | no Target Company shall: |
(i) | materially amend or terminate an agreement to which it is a party which involves total annual consideration or expenditure of €500,000, other in the usual course of its business; |
Page 29
(ii) | renew any insurance policy for a term greater than one year or without standard cancellation terms; or | ||
(iii) | fail to maintain its current levels of insurance coverage; |
(n) | no Target Company shall: |
(i) | establish a new Plan for or in respect of any director, officer, employee or consultant employed or engaged by any Target Company; | ||
(ii) | amend, or exercise a discretion, which increases pension scheme liabilities or employer costs in relation to, or discontinue (wholly or partly), any pension scheme applying to any director, officer, employee or individual independent contractor employed or engaged by any Target Company; | ||
(iii) | approve, direct or authorise any increase or decrease in the compensation, bonus, severance or fringe benefits of any director, officer, employee or individual independent contractor employed or engaged by any Target Company, except in the ordinary course of business and consistent with the past practice of the Target Companies; or | ||
(iv) | exercise any discretion to accelerate the vesting or payment of any compensation or benefit under any Plan payable to any director, officer, employee or individual independent contractor employed or engaged by any Target Company; |
(o) | no Target Company shall incur any new Financial Debt (other than any Financial Debt to another Target Company or any overdraft or other trading facilities utilised by Target Companies in the ordinary course of business) or allow any default under or breach of any provision of any document entered into by a Target Company concerning Financial Debt existing at the date of this Agreement; | |
(p) | no Target Company shall change or make any Tax elections, amend any Tax Returns where such amendment requires such Target Company to pay any amount of additional Tax, or take action which would reasonably be expected to change the Tax residency or jurisdiction of such Target Company, or to cause such Target Company to become subject to Tax in a jurisdiction in which such Target Company was not previously subject to Tax or undertake any merger or reorganisation for any Tax purposes; | |
(q) | with respect to Tax Returns filed by or on behalf of any Target Company, and with respect to Taxes payable by or on behalf of any Target Company, in each case during the period commencing upon (and including) the date of this Agreement and ending on (and including) the Closing Date, the Target Companies, save as required by law, shall prepare and file such Tax Returns, and calculate and pay such Taxes, in accordance with past practice, including, without limitation, past practice as to: |
(i) | positions taken, methods of accounting used, and principles of taxation followed; | ||
(ii) | elections made; | ||
(iii) | the processes and systems used in the preparation of Tax Returns, and the timing and manner for filing Tax Returns; |
Page 30
(iv) | the accounting periods used; | ||
(v) | the claiming of refunds of Tax; | ||
(vi) | the conduct of administrative or court proceedings related to Taxes; | ||
(vii) | the carryback or other utilisation of any tax relief; | ||
(viii) | the time of payment; and | ||
(ix) | all other material practices for the preparation and filing of Tax Returns and the payment of Taxes. |
For the avoidance of doubt, past practice shall not be taken to include late payment other than pursuant to an arrangement with the relevant Tax Authority; |
(r) | no Target Company shall grant any guarantee or indemnities outside the ordinary course of business; | |
(s) | no Target Company shall: |
(i) | enter into any settlement or compromise of any material dispute in respect of a claim, audit, or assessment by any Tax Authority with respect to Tax Returns or Taxes without the prior written approval of the Purchaser (such approval not to be unreasonably withheld or delayed); or | ||
(ii) | in the case of any claim, audit, or assessment by the Tax Authority in Sweden, enter into any settlement or compromise of any dispute with respect to Tax Returns or Taxes without the prior approval of the Purchaser or deliver or exchange any correspondence with any member of the Swedish Tax Authority or representative of the tax courts in Sweden concerning deductibility of any interest expense or costs incurred in relation to the raising or issuance of debt without the prior written approval of the Purchaser; and |
(t) | no Target Company shall agree to take any of the actions prohibited by paragraphs (c) through (s) above. |
(a) | approved by the Purchaser, in respect of paragraphs 1(a), 1(b), 1(c), 1(d), 1(h), 1(i), 1(j), 1(k), 1(l), 1(o), 1(p), 1(q), 1(r), 1(s) and 1(t); | |
(b) | approved by the Purchaser, such approval not to be unreasonably withheld or delayed, in respect of paragraphs 1(e), 1(f), 1(g), 1(m) and 1(n); | |
(c) | expressly contemplated, required or permitted by the terms of any Transaction Document, including in respect of any Permitted Leakage; | |
(d) | in connection with the employment of the following new full or part time persons in a senior managerial capacity: |
(i) | managing director (or equivalent position) in China; |
Page 31
(ii) | finance director (or equivalent position) in China; | ||
(iii) | vice president in respect of sales (or equivalent position) in Europe; | ||
(iv) | sales and marketing director (or equivalent position) in USA; | ||
(v) | cluster manager in Italy and France; | ||
(vi) | regulatory director in Japan; | ||
(vii) | any other person who is required as a direct replacement for any existing senior manager; |
(e) | in connection with the securitisation of the outstanding receivables in respect of debt owed by the suppliers of hospitals in the region of Campania, Italy in an amount not to exceed €2,000,000, on such terms as may be approved by the Purchaser (acting reasonably); | |
(f) | relating to the sale of the Uppsala Property as set out in clause 15; | |
(g) | in connection with the merger of Phadia Multiplexing Diagnostics GmbH and Phadia Austria GmbH; | |
(h) | in connection with the sale of any of the derivative assets, derivative liabilities and interest rate caps detailed in the Derivative Schedule; and | |
(i) | in connection with the sale of the shares held by a Target Company in Aerocrine AB. |
(a) | in connection with any appeal against the ruling of any Tax Authority in relation to the financial years ending on 31 December 2009 and 31 December 2010; and | |
(b) | in connection with any request to a Tax Authority for the deferral of Tax payable by the Target Companies. |
Page 32
1. | At Closing, the Seller shall deliver or ensure that there is delivered to the Purchaser (or made available to the Purchaser’s reasonable satisfaction): | |
(a) | a board resolution of the Seller (or, if required by the law of its jurisdiction or its articles of association, by-laws or equivalent constitutional documents, of its shareholders) authorising the execution of and the performance by the Purchaser of its obligations under this Agreement and each of the Transaction Documents to be executed by it; | |
(b) | a duly executed transfer into the name of the Purchaser in respect of the Shares; | |
(c) | the share register of the Company with the Purchaser duly registered as the new owner of the Shares as at the Closing Date; | |
(d) | a resolution of the board of Phadia US Inc. or, if appropriate, a resolution of any committee administering such company’s affairs, to terminate its 401(k) plan (defined contribution pension plan) with effect from the Closing Date or to take such other actions as are required to terminate such plan with effect from the Closing Date; | |
(e) | duly signed resignations in the Agreed Form of each of: |
(i) | Xxx Xxxxxx as a director of the Company, CB Diagnostics AB and Sweden DIA (Sweden) AB; | ||
(ii) | Xxxxxx XxXxxxxx as a director of the Company, CB Diagnostics AB, Sweden DIA (Sweden) AB and Phadia Holding AB; and | ||
(iii) | Xxxxxx Xxxxxxxxxxx as a director of Sweden DIA (Sweden) AB and Phadia Sweden AB; and |
(f) | a counterpart of the Escrow Agreement duly executed by it. |
1. | At Closing, the Purchaser shall: | |
(a) | deliver (or ensure that there is delivered to the Seller) a copy of a resolution of the board and/or supervisory board (as necessary to provide valid authorisation) of directors of the Purchaser (or, if required by the law of its jurisdiction or its articles of association, by-laws or equivalent constitutional documents, of its shareholders) authorising the execution of and the performance by the relevant company of its |
Page 33
obligations under this Agreement and each of the Transaction Documents to be executed by it; |
(b) | deliver evidence to the Seller of the valid issuance of the six year “run-off” directors’ and officers’ liability insurance policy purchased in accordance with clause 9.4; | |
(c) | pay by electronic funds transfer for value on the Closing Date the Share Price to the Seller’s Bank Account in accordance with clause 2.2; | |
(d) | deliver to the Seller (or ensure that there is delivered to the Seller) a counterpart of the Escrow Agreement duly executed by it and the Escrow Agent; and | |
(e) | comply with its obligations under clause 5.4 of this Agreement. |
(a) | delivery of all documents and all items required to be delivered at Closing (or waiver of the delivery of it by the person entitled to receive the relevant document or item); | |
(b) | receipt of an electronic funds transfer to the Seller’s Bank Account in immediately available funds of the Share Price; and | |
(c) | the prepayment and cancellation of all inter-company debt, the PIK Loan Agreement and the Facilities referred to in clause 5.4; |
Page 34
(a) | in the case of a person which is a body corporate, any subsidiary or parent company of that person and any subsidiary of any such parent company, in each case from time to time; | |
(b) | in the case of a person which is an individual, any spouse, co-habitee and/or lineal descendants by blood or adoption or any person or persons acting in its or their capacity as trustee or trustees of a trust of which such individual is the settler; | |
(c) | any Affiliate of any person in paragraphs (a) to (b) above. |
Page 36
Page 37
(a) | in each case to, or on behalf of, or for the benefit of the Seller or any of its Affiliates: |
(i) | any dividend or distribution (whether in cash or in kind) declared, paid or made by any Target Company; | ||
(ii) | any return of capital (whether by reduction of capital or redemption or purchase of shares) by any Target Company; | ||
(iii) | any fees (including directors’ fees, management fees or monitoring fees) paid by any Target Company (excluding any VAT in respect of the fees which is recoverable by the Target Companies by repayment or credit); | ||
(iv) | any transfer of an asset, right, value or benefit by any Target Company at an undervalue; and |
(b) | any payments made, or liabilities incurred, by any Target Company to any third party in connection with implementation of the Proposed Transaction (including any transaction or retention bonuses for management or adviser’s fees payable in connection with implementation of the Proposed Transaction and excluding any VAT and any other taxes payable or credited on such bonuses or fees), | |
(c) | but, in each case, does not include: (i) Permitted Leakage, (ii) the repayment of inter-company debt or the Facilities pursuant to clause 5.4, (iii) the repayment of the payment in kind facility entered into by the Company, or (iv) the payment of salary (including any associated social security payments), benefits or other emoluments, in the ordinary course of business, by a Target Company to any of its directors, officers or employees; |
Page 38
(a) | occurs after the date of this Agreement; | |
(b) | was not Fairly Disclosed by this Agreement, any other Transaction Document or any document disclosed in the Data Room; | |
(c) | directly results in cost or loss to the Target Companies in excess of €375 million, excluding, for the avoidance of doubt, any Indirect Damages and having set off any increase in the market value of the Target Companies caused by any other events which have occurred since the date of this Agreement, but excluding from the calculation of the amount of such reduction any loss, damage, costs or liability arising from the event to the extent that it has been remedied prior to Closing and/or the Target Companies have a right of compensation or recovery in respect thereof (whether by insurance or otherwise); and | |
(d) | does not, directly or indirectly, relate to or result from: |
(i) | changes in interest rates, exchange rates or securities or commodity prices or in economic, financial, market or political conditions (including any acts of war, civil unrest or other hostilities (or the escalation of such acts of war, civil unrest or other hostilities)) generally; | ||
(ii) | changes in conditions generally affecting the industry in which the Target Companies operate; | ||
(iii) | seasonal changes or any hurricane, tornado, flood, earthquake, volcanic eruption, other consequence of weather or any other natural disaster, or any acts of God, terrorist attacks, or any caution or recommendation against travel by any Governmental Entity, for whatever reason; |
Page 39
(iv) | the announcement of the signing of this Agreement or the pendency of the transactions contemplated hereby, including, in such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, vendors, investors or employees and the identity of the Purchaser and its Subsidiaries; | ||
(v) | changes in applicable laws, regulations or accounting practices; | ||
(vi) | any failure by the Target Businesses to meet any projections, guidance, estimates, forecasts or milestones for or during any period ending on or after the date of this Agreement (provided, however, that, except as otherwise provided in this definition, the underlying causes of such failure may be taken into account in determining whether a Material Adverse Change has occurred); | ||
(vii) | any transaction contemplated by any of the Transaction Documents or any change in control resulting from any such transaction; | ||
(viii) | any act or omission of the Purchaser or any member of the Purchaser Group; or | ||
(ix) | any act or omission of any member of the Seller or the Target Companies in the ordinary course of business or at the request or with the consent of the Purchaser or any member of the Purchaser Group or as required or permitted to be done under the terms of any of the Transaction Documents. |
Page 40
Page 41
(a) | any tax imposed in compliance with the Council directive of 28 November 2006 on the common system of value added tax (EC Directive 2006/112) (including, in relation to the UK, value added tax imposed by Value Added Tax Xxx 0000 and legislation and regulations supplemental thereto); and | |
(b) | any other tax of a similar nature, whether imposed in a member state of the European Union in substitution for, or levied in addition to, such tax referred to in (a), or elsewhere; and |
Page 42
(a) | references to a person include any individual, firm, body corporate (wherever incorporated), government, state or agency of a state or any joint venture, association, partnership, works council or employee representative body (whether or not having separate legal personality); | |
(b) | headings do not affect the interpretation of this Agreement; the singular shall include the plural and vice versa; and references to one gender include all genders; | |
(c) | references to any English legal term or concept shall, in respect of any jurisdiction other than England, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction; | |
(d) | any phrase introduced by the terms including, include, in particular or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms. |
Page 43
SIGNED
|
) | SIGNATURE: | /s/ Xxxxxxx Xxxxxx-Xxxxxxx | |||||
for and on behalf of
|
) | |||||||
CB DIAGNOSTICS
|
) | |||||||
LUXEMBOURG S.À X.X
|
) | NAME: | Xxxxxxx XXXXXX-XXXXXXX Manager |
|||||
SIGNED
|
) | SIGNATURE: | /s/ Xxxxxx XxXxxxxx | |||||
for and on behalf of
|
) | |||||||
CINVEN CAPITAL MANAGEMENT
|
) | |||||||
(IV) LIMITED as general
|
) | NAME: | XXXXXX XXXXXXXX | |||||
partner of CINVEN CAPITAL
|
) | |||||||
MANAGEMENT (IV) LIMITED
|
) | |||||||
PARTNERSHIP as general
|
) | |||||||
partner of FOURTH CINVEN
|
) | |||||||
FUND (NO.1) LIMITED PARTNERSHIP) |
||||||||
SIGNED
|
) | SIGNATURE: | /s/ Xxxxxx XxXxxxxx | |||||
for and on behalf of
|
) | |||||||
CINVEN CAPITAL MANAGEMENT
|
) | |||||||
(IV) LIMITED as general
|
) | NAME: | XXXXXX XXXXXXXX | |||||
partner of CINVEN CAPITAL
|
) | |||||||
MANAGEMENT (IV) LIMITED
|
) | |||||||
PARTNERSHIP as general
|
) | |||||||
partner of FOURTH CINVEN
|
) | |||||||
FUND (NO.2) LIMITED PARTNERSHIP) |
||||||||
SIGNED
|
) | SIGNATURE: | /s/ Xxxxxx XxXxxxxx | |||||
for and on behalf of
|
) | |||||||
CINVEN CAPITAL MANAGEMENT
|
) | |||||||
(IV) LIMITED as general
|
) | NAME: | XXXXXX XXXXXXXX | |||||
partner of CINVEN CAPITAL
|
) | |||||||
MANAGEMENT (IV) LIMITED
|
) | |||||||
PARTNERSHIP as general
|
) | |||||||
partner of FOURTH CINVEN
|
) | |||||||
FUND (NO.3 -VCOC)
|
) | |||||||
LIMITED PARTNERSHIP
|
) |
SIGNED
|
) | SIGNATURE: | /s/ Xxxxxx XxXxxxxx | |||||
for and on behalf of
|
) | |||||||
CINVEN CAPITAL MANAGEMENT
|
) | |||||||
(IV) LIMITED as general
|
) | NAME: | XXXXXX XXXXXXXX | |||||
partner of CINVEN CAPITAL
|
) | |||||||
MANAGEMENT (IV) LIMITED
|
) | |||||||
PARTNERSHIP as general
|
) | |||||||
partner of FOURTH CINVEN
|
) | |||||||
FUND (NO.4) LIMITED PARTNERSHIP) |
||||||||
SIGNED
|
) | SIGNATURE: | /s/ Xxxxxx XxXxxxxx | |||||
for and on behalf of
|
) | |||||||
CINVEN CAPITAL MANAGEMENT
|
) | |||||||
(IV) LIMITED as general
|
) | NAME: | XXXXXX XXXXXXXX | |||||
partner of CINVEN CAPITAL
|
) | |||||||
MANAGEMENT (IV) LIMITED
|
) | |||||||
PARTNERSHIP as general
|
) | |||||||
partner of FOURTH CINVEN
|
) | |||||||
FUND (UBTI) LIMITED
|
) | |||||||
PARTNERSHIP
|
) | |||||||
SIGNED
|
) | SIGNATURE: | /s/ Xxxxxx XxXxxxxx | |||||
for and on behalf of
|
) | |||||||
CIP (IV) NOMINEES LIMITED
|
) | |||||||
acting on behalf of FOURTH CINVEN
|
) | NAME: | XXXXXX XXXXXXXX | |||||
FUND CO-INVESTMENT
|
) | |||||||
PARTNERSHIP
|
) | |||||||
SIGNED
|
) | SIGNATURE: | /s/ Xxxxxx XxXxxxxx | |||||
for and on behalf of
|
) | |||||||
CINVEN CAPITAL MANAGEMENT
|
) | |||||||
(IV) LIMITED as general
|
) | NAME: | XXXXXX XXXXXXXX | |||||
partner of CINVEN CAPITAL
|
) | |||||||
MANAGEMENT (IV) LIMITED
|
) | |||||||
PARTNERSHIP as general
|
) | |||||||
partner of FOURTH CINVEN (MACIF)
|
) | |||||||
LIMITED PARTNERSHIP
|
) | |||||||
SIGNED
|
) | SIGNATURE: | /s/ Geismaan | |||||
for and on behalf of
|
) | |||||||
CINVEN SA as manager of
|
) | |||||||
FOURTH CINVEN FUND FCPR
|
) | NAME: | X. GEISMAAN | |||||
SIGNED
|
) | SIGNATURE: | /s/ Xxxx X. Xxxxxxxxx | |||||
for and on behalf of
|
) | |||||||
THERMO XXXXXX SCIENTIFIC INC.
|
) | NAME: | XXXX X. XXXXXXXXX | |||||